FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 10 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 21, 2023 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Fate Therapeutics
- Interventions being studied
- Drug: FT536; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: IL-2; Combination Product: Avelumab; Combination Product: Pembrolizumab; Combination Product: Nivolumab; Combination Product: Atezolizumab; Combination Product: Trastuzumab; Combination Product: Cetuximab; Combination Product: Amivantamab; Drug: IL-2
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Participants with locally advanced or metastatic disease who have progressed/relapsed, are refractory, intolerant to or refuse standard therapy approved for their specific tumor type: Cohort A/A2/AA/AA2: NSCLC, CRC, BC, ovarian cancer, or pancreatic cancer Cohorts B/B2/BB/BB2 and C/C2/CC/CC2: Subjects with NSCLC, HNSCC, gastroesophageal adenocarinoma, triple negative breast cancer, or urothelial carcinoma whose tumors express PD-L1 according to defined cutoff Cohort D/D2/DD/DD2: Subjects with advanced solid tumor whose tumor(s) express HER2 defined as: ≥2+ by IHC, Average HER2 copy number ≥4 signals per cell by in situ hybridization or ≥4 copies as determined by next generation sequencing Cohort E/E2/EE/EE2: Squamous NSCLC; head and neck cancer that relapsed or progressed following prior cetuximab treatment; CRC subjects who are KRAS/NRAS/BRAF wild-type are required to have progressed/relapsed on prior cetuximab or panitumumab Cohort F/F2/FF/FF2: NSCLC known to have at least one of the following: epidermal growth factor receptor (EGFR) driver mutation(s) and have progressed on or were intolerant to at least one prior line of EGFR Tyrosine Kinase Inhibitor (TKI) or were not candidates for or declined TKI; mesenchymal-epithelial transition (MET) exon 14 skipping mutation that has progressed on or intolerant of at least one prior line of MET TKI or were not candidates for or declined TKI; MET amplification defined as MET/CEP7 ratio ≥1.8 by Fluorescence in situ hybridization (FISH)
- Has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- For subjects with \>1 measurable lesion by RECIST v1.1 that can be safely accessed, willingness to undergo tumor biopsy
- Agrees to contraceptive use for women and men as defined in the protocol
- Is a pregnant or breast-feeding female
- Has Eastern Cooperative Oncology Group (ECOG) performance status ≥2
- Has evidence of insufficient organ function
- Has clinically significant cardiovascular disease including left-ventricular ejection fraction \< 45%
- Has received any therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter or any investigational therapy within 28 days prior to Day 1
- Has a known active malignancy in the central nervous system (CNS) that hasn't remained stable for at least 3 months following effective treatment for CNS disease
- Has a non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or neurodegenerative disease or receipt of medications for these conditions
- Has had any active malignancy other than those studied in this trial within 2 years of the first dose of study therapy
- Is currently receiving or likely to require immunosuppressive therapy
- Has an active bacterial, fungal, or viral infections including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Has received a live vaccine within 6 weeks prior to start of lympho-conditioning
- Has a known allergy to albumin (human) or dimethyl sulfoxide (DMSO)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Honor Health Research InstituteScottsdale, Arizona
- UCLA Division of Hematology-OncologyLos Angeles, California
- Hackensack University Medical Center - John Theurer Cancer CenterHackensack, New Jersey
- Carolina BioOncology InstituteHuntersville, North Carolina
- NEXT OncologySan Antonio, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 21, 2023. Always confirm current availability with the study team.